Stay updated with breaking news from Nasdaq Srpt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reissued by Needham & Company LLC in a report issued on Monday, Benzinga reports. They presently have a $140.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s price target suggests a potential upside of 15.05% from the company’s previous close. […]
NBC Securities Inc. purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 6,160 shares of the biotechnology company’s stock, valued at approximately $746,000. Several other institutional investors also […]
California Public Employees Retirement System trimmed its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 2.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 164,457 shares of the biotechnology company’s stock after selling 3,649 shares during the period. […]
California Public Employees Retirement System cut its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 2.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 164,457 shares of the biotechnology company’s stock after selling 3,649 shares during the quarter. California Public Employees […]
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its target price lowered by equities research analysts at Royal Bank of Canada from $155.00 to $151.00 in a report released on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Royal Bank of Canada’s target price indicates a potential upside […]